Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review Article

Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic

Maryam Sharifian-Dorchea,b, Philippe Huota, Michael Osherova, Dingke Wena,c, Alexander Saverianoa, Paul S Giacominia, Jack P Antela, Ashkan Mowla,a,d

a Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
b Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
c Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
d Department of Neurological Surgery, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA

ARTICLE INFO

Key Words:
COVID-19
SARS-CoV-1
MERS-CoV
Neurological manifestations
Coronavirus

ABSTRACT

Introduction: Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. Several studies have been performed, focusing on understanding the acute respiratory syndrome and treatment strategies. However, there is growing evidence indicating neurological manifestations occur in patients with COVID-19. Similarly, the other coronaviruses (CoV) epidemics; severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV) have been associated with neurological complications. Methods: This systematic review serves to summarize available information regarding the potential effects of different types of CoV on the nervous system and describes the range of clinical neurological complications that have been reported thus far in COVID-19. Results: Two hundred and twenty-five studies on CoV infections associated neurological manifestations in human were reviewed. Of those, 208 articles were pertinent to COVID-19. The most common neurological complaints in COVID-19 were anosmia, ageusia, and headache, but more serious complications, such as stroke, impairment of consciousness, seizures, and encephalopathy, have also been reported. Conclusion: There are several similarities between neurological complications after SARS-CoV-1, MERS-CoV and COVID-19, however, the scope of the epidemics and number of patients are very different. Reports on the neurological complications after and during COVID-19 are growing on a daily basis. Accordingly, comprehensive knowledge of these complications will help health care providers to be attentive to these complications and diagnose and treat them timely.

1. Introduction

Coronavirus disease-19 (COVID-19) pandemic continues to grow all over the world. [1] Currently, several research studies have been performed, focusing on the understanding of the acute respiratory syndrome and treatment strategies. [1] However, there is growing evidence of the neurological manifestations in patients with COVID-19. Similarly, the other coronaviruses (CoV) epidemics; severe acute respiratory syndrome (SARS-CoV-1) and Middle East respiratory syndrome (MERS-CoV) have been associated with neurological complications. CoV neurotropism, direct invasion of the virus to the central nervous system (CNS) and post infection neurological complications were suggested as the cause of these presentations. [1]

1.1. History

Viral respiratory infection pandemic is not a new event in medical history. Reports of respiratory infection outbreaks back to 1173 AD. The first confirmed pandemic of respiratory infections, occurred in 1580. [2] More recently, in the 20th and 21st centuries, there have been several reposts of such pandemics and outbreaks, including the Spanish Flu pandemic of the early 20th century, SARS-CoV-1 epidemic in 2003 and MERS-CoV outbreak in 2012. [1,2] Neuropsychiatric complications during and after these pandemics have been noticed by many scientists. One of the first neurological presentations, which was reported after the 1580 pandemic was encephalitis. [3] The Spanish Flu Pandemic in 1918 was the first respiratory infection

https://doi.org/10.1016/j.jns.2020.117085

Received 4 August 2020; Accepted 5 August 2020
Available online 07 August 2020
0022-510X/ © 2020 Elsevier B.V. All rights reserved.
pandemic in the 20th century. It infected over 500 million people worldwide. [3] Several investigations were performed during and after the pandemic on neuropsychiatric symptoms, treatments, and delayed complications. It was reported that many patients who recovered from the respiratory symptoms of the disease had very pronounced nervous system sequelae, such as depression, neurasthenia, acute post-flu psychosis, and neuritis, some persisting until one year after the illness. [4]

Besides these neurological presentations, which were considered to be caused directly by the infection, scientists believe that an autoimmune response might have caused delayed neurological complications in these patients. [5] As an example, Encephalitis lethargica, a neurological syndrome which widely coincided with, and lasted for a decade after the Spanish Flu pandemic, was believed to be in relation to the influenza infection. [5] Moreover, despite controversies, it was shown that Parkinson’s disease was born or were young at the time of the Spanish Flu pandemic. [5]

With respect to the current pandemic, we reviewed the neurological complications of CoV infection in human.

1.2. CoV

CoV are large, enveloped, positive-sense RNA viruses. They infect humans and several groups of the animal species. They generally cause upper and lower respiratory tract and gastrointestinal infections, hepatitis or neurological manifestations. Human coronaviruses (HCoV) which causes human infections were first discovered in 1965. [6] Until now seven types of CoV have been discovered: SARS-CoV-2, SARS-CoV-1, and MERS-CoV which are associated with the three epidemics and caused severe disease in humans, HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU1. [7] CoV may invade the CNS, disseminate, and participate in induction of neurological diseases. Before SARS-CoV-2, three other types including: SARS-CoV-1, HCoV-229E and HCoV-OC43 had been shown to cause CNS infection. [7]

2. Methods

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Figure 1) statement. [8] We searched PubMed till July 7, 2020 for HCoV-229E and HCoV-OC43 (Part A, B), from Jan 1, 2000, to July 7, 2020, for SARS-CoV-1 (part C), from Jan 1, 2010, to July 7, 2020, for MERS-CoV (Part D) and from Jan 1, 2020, to July 7, 2020, for Covid-19 (Part E). These Keywords were used:

Part A: “HCoV-229E” AND “Neuro” OR “Brain”
Part B: “HCoV-OC43” AND “Neuro” OR “Brain”
Part C: “Severe acute respiratory syndrome of Coronavirus” OR “SARS” AND “Neuro” OR “Brain”
Part D: “Middle East respiratory syndrome coronavirus” OR “MERS” AND “Neuro” OR “Brain”
Part E: “Coronavirus” OR “COVID” AND “Neuro” OR “Brain”

Articles written in English were included. The authors evaluated the titles and abstracts of each article for screening and inclusion. Articles evaluating CoV infections with respect to the neurological complications in human (original articles and reports of the cases (case series, case reports, letters, correspondence, or short communications which presented at least 1 case)) were reviewed in full text by the authors and included. (In COVID-19 we just included the studies which described neurological symptoms in adults) Studies not related to the CoV infections or their neurological manifestations were excluded from the review. Duplicated results were removed. We also reviewed relevant references in each article. Data from each article was extracted into the Microsoft Excel software.

3. Results and discussion

3.1. HCoV-OC43 and HCoV-229E

CNS damages caused by HCoV was suggested in the 1980s. In 1980 Burks JS et al. [10] isolated CoV from the brains of two MS patients. Subsequently the hypothesis concerning the relationship between CoV infection and demyelinating diseases in humans CNS was studied several times. [10,11,12] Arbour N et al showed that human CNS cells including oligodendrocytes, astrocytes, microglia, and neurons are susceptible to acute infection with HCoV-OC43 during in vitro cultures, and other than microglia, the rest have a potential of persistent infection. [13] In animal studies, direct invasion of the virus via nasal canal caused a rapid CNS infection. [14] Cristallo A et al [11] reported presence of HCoV-OC43 RNA in the Cerebrospinal fluid (CSF) of MS patients; However, Dessau RB et al. [12] did not find any evidence of chronic 229E or OC43 infection in brain tissue of MS patients. In 1992, Fazzini E et al showed higher levels of HCoV-OC43, and HCoV-229E antibodies in CSF of Parkinson disease patients compared to controls. [9]

Two cases of fatal encephalitis with HCoV-OC43 infection were reported in 2 immunosuppressed infants (9-month old infant on
chemotherapy for leukemia and 11-month boy with severe combined immunodeficiency). [15,16] Moreover, acute disseminated encephalomyelitis (ADEM) was reported with HCoV-OC43 infection in a 15-year-old boy. In this case, CSF was positive for the virus. [17] In 2015, acute flaccid paralysis was reported in a 3-year-old girl after infection with HCoV 229E and OC43 [18] In another study by Li Y et al. [19] from China, CoV was suggested as an important cause of acute encephalitis-like syndrome in children.

3.2. SARS-CoV-1

The outbreak of SARS-CoV-1 was in 2002-2003 and affected more than 8,000 people worldwide. [20] Clinical presentations in most of the patients were a simple common cold. However, in patients with an impaired immune system, it caused respiratory distress, pneumonia, and even death. [20] In some of these patients, neurological complications were reported. (Table 1) [21–28]. Cerebrovascular pathologies and ischemic strokes were reported in 5 patients. Most of these patients had severe infection and several comorbidities, which might have made them more susceptible to stroke. [21] In these cases, hypo-perfusion as result of septic shock, utilization of intravenous immunoglobulin as a part of the treatment regimen, hypercoagulability state, cardiogenic shock, and vasculitis might represent the potential underlying mechanisms for the cerebrovascular events. [21]

Encephalitis was reported in a 39-year-old patient. In his autopsy, SARS-CoV-1 RNA was isolated from the specimen and virions were visualized in neurons on electron microscopy. [24] Other studies on brain tissue specimens of autopsy donors detected SARS-CoV-1 in the cytoplasm of neurons in the cortex and hypothalamus. [29] Neuroptathy and myopathy were seen in 9 patients. Tsai LK, et al. [25] reported patients with different types of Guillain-Barré syndrome (GBS) (acute inflammatory demyelinating polyneuropathy(AIDP) and acute motor axonal neuropathy (AMAN)). Chao CC et al. [26] described a patient with critical illness polyneuropathy. Myopathy was reported in 5 patients. [25,28] (Table 1)

Despite many suggested that those complications were caused by the direct attack of the virus to the nerves and muscles, critical illness neuropathy and myopathy should be considered as another potential underlying cause. In the case of myopathy, many of these patients were treated with corticosteroids for the primary illness and steroid-induced myopathy might have been a differential diagnosis in such patients. [25,28]

### Table 1

| No. | Neurological Symptom | Ref. No. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|----------------------|----------|-----------------|----------------------------------|-------|
| 1   | Ischemic stroke      | [21]     | 5 Patients      | 57.6(39–68)                      | Large artery ischemic stroke especially in critically ill patients. |
| 2   | Headache             | [22]     | F               | 62                               | CSF positive for SARS-CoV-1 |
| 3   | Seizure              | [23]     | F               | 32                               | Autopsy tissue from the patient revealed neuronal necrosis, glial cell hyperplasia, and infiltration of monocytes and T cells. |
| 4   | Myopathy             | [24]     | M               | 39                               | Leung TW et al. [28] study was a post-mortem study, steroid-induced myopathy suggested for these patients. (4 cases) |
| 5   | Guillain-Barré syndrome (GBS) | [25] | 3F | 47(42–51) | Both acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) |
| 6   | Critical illness polyneuropathy | [26] | F | 51 | |
| 7   | Malignant hyperplasia | [27] | F | 27 | |
| 8   | Smell impairment     | [28]     | S M             | 54.8(31–81)                      | |

Abbreviation: M: Male, F: Female

3.3. MERS-CoV outbreak

MERS or Camel Flu caused by the MERS-CoV, was first identified in 2012 in Saudi Arabia and caused outbreaks in South Korea and Saudi Arabia. Symptoms varied from none or mild common cold such as fever, myalgia, and cough to acute respiratory distress syndrome (ARDS), sepsis, multi-organ failure, and even death. [30] About 2500 confirmed cases were detected worldwide, and the fatality rate was reported as 34.3%. [31]

Prevalence of neurological complications were high among patients with MERS-CoV infection. In a study by Saad M et al. [32] 29 out of 70 patients with MERS-CoV infection had neurological manifestations. Serious neurological complications such as ischemic stroke and encephalitis were also reported in these patients. (Table 2) Some of these complications did not coexist with the respiratory symptoms and were delayed for approximately 2–3 weeks later. [36] Intracranial hemorrhage (ICH) was reported in 2 patients; in one, an abnormal coagulation panel and disseminated intravascular coagulation (DIC) were noted leading to severe multiple organ failure, but the other patient had a normal coagulation panel and platelet count. [34,35] Both patients were women and relatively young.

Contrarily to the fact that CNS infection were confirmed in animal models after intranasal inoculation with MERS-CoV, the virus has never been detected in the CNS of humans. [37]

3.4. COVID 19 pandemic

To date there are several reports on neurological complications of COVID-19. We divided the neurological symptoms in such patients into three different groups: symptoms related to CNS involvement [38–214], symptoms related to the peripheral nervous system (PNS) involvement, and symptoms related to skeletal muscle injury or neuromuscular junction (NMJ) disorder. We also emphasize important clinical points in each case. (Table 3,4,5)

Studies were performed in 25 different countries; the United States with 46 publications had the highest number of publications on this topic. (Figure 2) The most common neurological symptoms in COVID-19 are headache, dizziness, anosmia, and ageusia. More severe neurological findings include stroke, impairment of consciousness, coma, seizures, neuropathy, and encephalopathy. (Figure 3)

3.4.1. Symptoms related to CNS

3.4.1.1. Headache and dizziness. Headache and dizziness have been reported as two of the most common initial presentations in many
patients with COVID-19. These two are very common symptoms in many neurological pathologies such as meningitis, encephalitis and vasculitis. It was shown that they can also occur in temporal association with a systemic viral infection. [38,39,40]

In COVID-19, headache has been reported in 2073 patients in 34 studies. (Table 3) The severity of headache was reported to be moderate to severe. Headaches were reported to have tension-type quality, [69] pain was reported to be bilateral with exacerbation by bending over, and mostly located in the temporo-parietal region or sometimes more anteriorly toward the forehead. [38] In most of these patients, headaches occurrence was associated with a past medical history of headaches. [69]

Several potential underlying pathophysiological mechanisms were suggested, particularly for headaches in the forehead and periorbital regions [38]; notably, it could be due to a direct invasion of SARS-CoV-2 to the trigeminal nerve endings in the nasal cavity. The other proposed underlying mechanism is trigemino-vascular activation due to involvement of the endothelial cells of the vessel walls with high expression of angiotensin-converting enzyme 2 (ACE2). A third proposed mechanism, the release of the pro-inflammatory mediators and cytokines during COVID-19 might stimulate the perivascular trigeminal nerve endings and cause headache. [38] We summarized the studies which reported Headache and dizziness in patients with COVID-19 in Table 3.

Eleven studies reported dizziness as one of the presenting symptoms of COVID-19 in 173 patients. (Table 3) Kong Z et al. [72] reported a 53-year-old woman with dizziness as the initial symptom of COVID-19.

### 3.4.1.2. Cerebrovascular events

**Acute Ischemic stroke(AIS)** has been reported in approximately 1-3% of patients with COVID-19 [39,77,84]; this is similar with other CoV infections (SARS-CoV-1 and MERS-CoV). During the current pandemic, 370 patients with SARS-CoV-2 infection out of 37 studies (Table 3) were reported to suffer from AIS or transient ischemic attack (TIA). Most of these patients had several underlying comorbidities which made them more susceptible to thromboembolic events. [21,77].

However, there are reports on AIS occurring in young adults with SARS-CoV-2 infection and without any past medical history or cardiovascular risk factors. [80,85,95] (Figure. 4). Systemic effects of SARS-CoV-2 might be the underlying mechanism in these cases. Coagulation abnormalities have been shown in critically ill COVID 19 patients. This was characterized by rise in procoagulant factors, including serum levels of fibrinogen (94%), platelet (62%), interleukin-6 (IL-6) and D-dimer (100%) which subsequently may contribute to elevated rate of thromboembolic events and higher rate of mortality and morbidity. [103]. SARS-CoV-2 may cause an inflammatory response in the body. Elevated levels of C-reactive protein (CRP), interleukin-7 (IL-7), IL-6 and other inflammatory markers makes the existing atherosclerotic plaque more susceptible to rupture [84]. Cardiac manifestations and arrhythmic complications of COVID-19 can be another potential mechanism contributing to higher rate of ischemic events in these patients. [104]. The other proposed mechanism involves ACE2. It was shown that SARS-CoV-2 virus binds to ACE2 which is located in the lung, small intestinal and brain vessel endothelial cells. Depletion of ACE2 by SARS-CoV-2 virus may cause imbalance of the renin angiotensin system (RAS) which might result in endothelial dysfunction and subsequently ischemic events. [105]

**Intracranial Hemorrhage (ICH)** was seen in about 0.5% of the patients with COVID-19 in large population studies. [39,60] Overall 61 patients in 19 studies were reportedly presented with ICH. (Table 3) In the past CoV pandemic, ICH was reported as a neurological complication with MERS-CoV infection [34,35]. In critically ill patients, COVID-19 has been associated with coagulopathies such as DIC, thrombocytopenia, elevated D-dimer, and prolonged prothrombin time which can result in hemorrhage. [113] Another potential mechanism is the effect of SARS-CoV-2 on ACE2. As mentioned earlier, SARS-CoV-2 has been shown to use the ACE 2 receptor for cell entry. ACE2, the SARS-CoV-2 binding site, is a critical component of the counter-regulatory pathway of the RAS, which is one of the most important regulators of blood pressure. SARS-CoV-2-induced ACE2 downregulation may lead to vasoconstriction and dysfunction of cerebral autoregulation and subsequently blood pressure spikes which eventually can cause arterial wall rupture and hemorrhage. [106]. There are reports that suggested even neurosurgical interventions were accompanied with more hemorrhagic complications in patients with COVID-19. [113]

**Cerebral Venous Sinus Thrombosis** was reported in 13 patients out of 9 studies. (Table 3) Overall it was shown that venous and arterial thromboembolic complications are seen in 5–15% of patients with severe COVID-19. [119] Combination of low-grade DIC and a localized pulmonary thrombotic micro-angiopathy might be the cause. The COVID-19 coagulopathy is characterized by a significant increase in D-dimers, high fibrinogen levels, mild prolonged prothrombin time, and a modest thrombocytopenia. [114,119] Besides, in patients with COVID-19 a transient raise of antiphospholipid antibodies is seen which may play a role in pathophysiology of thrombosis. [114,119] Cytokine storm particularly in critically ill COVID-19 patients is the other possible mechanism. It suppresses the anticoagulant pathways and release von Willebrand factor which might lead to thrombosis in such patients. [119]

### 3.4.1.3. Demyelinating diseases

As of now, five patients with ADEM have been reported after CoV infection; one adolescent with HCoV-

| No. | Neurological Symptom | Ref. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|----------------------|------|----------------|-------------------------------|-------|
| 1   | Ischemic stroke      | [33] | 2M             | 65.6(57-74)                   |       |
| 2   | Intracranial hemorrhage (ICH) | [34], [35] | 2F             | 38(34–42)                      | ICH in one of the patients was related to DIC and thrombocytopenia but the other patient had normal coagulation at the time of ICH. |
| 3   | Headache             | [32] | 9 (12.9%)       | NR                            |       |
| 4   | Seizure              | [32] | 6(6.6%)         | NR                            |       |
| 5   | Confusion            | [32] | 18 (25.7)       | NR                            |       |
| 6   | Encephalitis         | [36] | M 45           | CSF: Not significant          |       |
| 7   | Bickerstaff's encephalitis overlapping with GBS | [36] | M 55          |       |

**Symptoms related to Peripheral nervous system (PNS)**

| No. | Neurological Symptom | Ref. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|----------------------|------|----------------|-------------------------------|-------|
| 8   | Guillain-Barré syndrome (GBS) | [34], [36] | 4 patients 2M 2F | 38.7(28–46)               |       |

**Table 2**

**Neurological Complications Reported During and After MERS-CoV Infection.**

| Ref. No. of patients | Mean Age of the patients (Range) | Notes |
|----------------------|---------------------------------|-------|
| 34                   | 2F                             |       |
| 35                   | 2M                             |       |
| 36                   | M                              |       |
| 37                   | M                              |       |

**Abbreviation:** M. Male; F. Female
### Table 3
CNS Complications Reported During and After SARS-CoV-2 Infection.

| No. | Neurological Symptom          | Ref. No.                                                                 | No. of patients | Mean Age of the patients (Range) | Notes                                                                 |
|-----|-------------------------------|--------------------------------------------------------------------------|----------------|----------------------------------|----------------------------------------------------------------------|
| 1   | Headache                      | [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67], [68], [69], [70], [71], [72] | 2073           | NR in all articles.             | Kong Z et al. [72] reported a 53 Y/O F with dizziness as the first presentation of COVID-19. |
| 2   | Dizziness                     | [39], [43], [47], [48], [57], [60], [62], [69], [70], [71], [72]       | 173            | NR in all articles.              | In large population studies ischemic stroke was reported in 1% [77] to 2.5% [84] of patients. |
| 3   | Ischemic Stroke               | [39], [57], [58], [60], [63], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94], [95], [96], [97], [98], [99], [100], [101], [102], [178], [192] | 363            | NR in all articles.             | Young adult patients without any past medical history [80] and patients with large-vessel stroke were reported. [80,85,95] |
|     |                               |                                                                         |                |                                  | One 38 Y/O F patient with stroke and CADASIL was reported. [89]      |
| 4   | TIA                           | [50], [75], [94]                                                       | 7              | NR in all articles.              | A 67 Y/O M simultaneous cerebral infarcts in multiple arterial territories were reported. [91] |
| 5   | Cerebral Hemorrhage           | [39], [57], [58], [60], [63], [73], [86], [92], [98], [99], [100], [101], [106], [107], [108], [109], [110], [111], [112] | 61             | NR in all articles.             | Muhammad S et al. [107] reported a 60 Y/O F with aneurysm and ICH.    |
| 6   | Cerebral Venous Sinus Thrombosis | [90], [101], [102], [114], [115], [116], [117], [118], [119] | 13             | NR in all articles.             | Ghosh R, et al. [111], reported a 19 Y/O F with Moyamoya Angiopathy and ICH. |
| 7   | Acute disseminated encephalomyelitis (ADEM) | [120], [121], [122], [123] | 4              | 61(51–71)                       | Reichard RR et al. [122], study reported post-mortem examinations of a 71 Y/O M which revealed ADEM-like appearance at the brain biopsy. |
| 8   | Acute Myelitis                | [125], [126], [127], [128], [129]                                    | 2              | 2F                              | In one of these patients [125] CSF or MRI exam was not performed.      |
|     |                               |                                                                         |                |                                  | Sotoca J et al. [127], reported 69 y/o F acute necrotizing myelitis.   |
| 9   | Optic Neuritis                | [60]                                                                    | 1              | NR                              | Giorgianni A, et al. [128] reported a 22 Y/O F with transient acute-onset tetra paresis with normal MRI and CSF exam. |
| 10  | Acute encephalomyelitis       | [132], [179], [187], [196]                                            | 4              | 21-54                           | Zoghi A et al. [132], reported 21 Y/O M suspicious to ADEM or neuromyelitis-optica spectrum disorder. |
|     |                               |                                                                         |                |                                  | Zanin L, et al. [179] reported a 54 Y/O F with seizure and brain and spine demyelinating lesions. |
|     |                               |                                                                         |                |                                  | Brun G et al. [187] reported a 54 Y/O F with Multiple supra-tentorial punctiform and tumefactive lesions involving the white matter bilaterally. |

(continued on next page)
| No. | Neurological Symptom                                      | Ref. No.                                                                 | No. of patients | Mean Age of the patients (Range) | Notes                                                                                           |
|-----|----------------------------------------------------------|--------------------------------------------------------------------------|-----------------|----------------------------------|-------------------------------------------------------------------------------------------------|
| 11  | Decreased level of consciousness And Encephalopathy    | [59], [69], [77], [59], [60], [62], [88], [96], [98], [109], [101], [133], [135], [136], [137], [139], [140], [141], [178], [184], [189], [193], [197] | 4,54            | NR in all articles               | Demirci Othougu G et al. [196] reported a 48 Y/O M with Acute encephalomyelitis and positive CSF for SARS-CoV2 |
| 12  | Leukoencephalopathy                                     | [144], [145], [188]                                                    | 18              | NR in all articles               | Yin R et al. [133] reported a 64 Y/O M with altered consciousness and Psychiatric symptoms, his brain CT scan was Normal. |
| 13  | Acute Necrotizing Encephalopathy(ANE)                   | [146], [147], [148], [149], [178], [193]                                | 8               | NR in all articles               | Farhadian S et al. [138], reported a 78 Y/O F with acute encephalopathy and elevated CSF inflammatory markers. |
| 14  | Encephalitis                                            | [60], [98], [100], [150], [151], [152], [153], [154], [155], [156], [157], [158] | 22              | NR in all articles               | Hosseini AA et al. [139], reported 2 patients (46 Y/O, 79 Y/O) F with Delirium as a presenting feature in COVID-19, neuro-invasion or autoimmune encephalopathy was suggested as the cause. |
| 15  | Mild encephalitis/encephalopathy with a Reversible Splenial Lesion(MERS) | [160]                                                                    | 1               | 75                              | Kulick-Soper CV, et al. [189] reported a 54 Y/O F with bilateral globus pallidus lesions and possibility of hypoxic brain damage. |
| 16  | Posterior reversible encephalopathy syndrome (PRES).    | [50], [101], [161], [162], [163], [164], [165], [199]                   | 10              | NR in all articles               | Radmanesh A et al. [145], reported 4 patients with leukoencephalopathy one patient with micro-hemorrhages and six patients with both presentations. |
| 17  | Seizure                                                 | [39], [58], [69], [63], [101], [150], [156], [166], [167], [168], [169], [170], [171], [172], [173], [174], [175], [176], [177], [178], [179] | 48              | NR in all articles               | Logmin K et al. [171], reported a 70 Y/O patient with non-epileptic seizures.                   |

(continued on next page)
Table 3 (continued)

| No. | Neurological Symptom | Ref. No. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|-----------------------|----------|-----------------|---------------------------------|-------|
|     |                       |          |                 |                                 |       |
| 18  | Movement disorders    | [182], [183] | 4               | 71.25(58-88)                   |       |
|     | Generalized Myoclonus, |          |                 |                                 |       |
|     | Hypokinetic-rigid syndrome |        |                 |                                 |       |
|     | CNS Vasculitis         | [98], [185], [186] | 2               | NR in all articles. |       |
| 19  | Cranial Nerve abnormalities | [39], [56], [57], [58], [62], [69], [101], [183], [188], [198], [199], [200], [201], [203], [204], [205], [206], [207], [208], [209], [210], [211], [212], [213], [214], [200], [201], [203] | 3730 | NR in all articles. | Mermelstein S [202] a 27 Y/O neurology registrar, reported her symptoms and anosmia after COVID-19. |
| 20  | Anosmia                | [39], [56], [57], [58], [62], [69], [101], [183], [188], [198], [199], [200], [201], [203], [204], [205], [206], [207], [208], [209], [210], [211], [212], [213], [214], [200], [201], [203] | 12   | NR in all articles. |       |
| 21  | Ageusia                | [39], [56], [57], [58], [62], [69], [101], [183], [188], [198], [199], [200], [201], [203], [204], [205], [206], [207], [208], [209], [210], [211], [212], [213], [214], [200], [201], [203] | 2590 | NR in all articles. |       |
| 22  | Impaired Vision        | [39], [57], [204] | 12               | NR in all articles. |       |

Abbreviation: M: Male, F: Female, NR: Not reported.
OC43 [17] and 4 adults after SARS-CoV-2. [120–123] relation between CoV infections and demyelinating diseases of CNS has been suggested in last decades. [12,124] Despite the fact of ADEM usually occurring in children [17], in the current pandemic all reported ADEM patients were older than 50-year-old. This finding might be due to higher prevalence of COVID-19 in adults. From the reported patients, two recovered with methylprednisolone and intravenous immunoglobins [120,121] and two of them died [122,123], one was a 71-year-old-man with underlying comorbidities and ADEM was diagnosed in post-mortem biopsy. [122] The other one was a 58-year-old man who was treated with dexamethasone and died as consequence of status epilepticus. [123] (Figure. 5)

**MS Exacerbation:** Early insights about COVID-19 in MS patients suggest that the risk of infection and associated morbidity in this population is not significantly different from the non-COVID19 patients [130]. Moreover, worsening outcome with regards to with disease-modifying therapies has not been reported. [131]

**Acute encephalomyelitis** in COVID-19, were reported in 4 patients. (Table 3) Zoghi et al. reported a 21-year-old-man with encephalomyelitis following SARS-CoV-2 infection. The patient reported having upper respiratory infection symptoms for 2 weeks prior to this presentation. [132] Based on the clinical and brain MRI findings, there was suspicion of ADEM or neuromyelitis optica spectrum disorder (NMOSD) following COVID-19. In another study, Demirci Otluoglu G et al. [196] reported a 48-year-old man with acute encephalomyelitis and positive CSF for SARS-CoV-2.

**Acute Myelitis** was reported in 5 patients after COVID-19. [125–129] It was shown that 30–60% of idiopathic transverse myelitis cases are associated with an antecedent respiratory, gastrointestinal, or systemic illness. [126] In the recent reported patients, post-infectious etiology in terms of secondary immunogenic overreaction was proposed as the underlying mechanism for myelitis after COVID-19. [125] Sotoca

### Table 4
**PNS Complications Reported During and After SARS-CoV-2 Infection.**

| No. | Neurological Symptom                  | Ref. No. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|---------------------------------------|----------|----------------|----------------------------------|-------|
| 1   | Cranial Nerve abnormalities            |          |                |                                  |       |
| 1   | Impaired Eye movement                  | [57], [58], [194], [215] | 12 | NR in all articles. | Pascual-Goñi E et al. [194], reported a 36 Y/O F and bilateral sixth nerve palsy with impression of Wernicke encephalopathy. |
| 2   | Trigeminal neuropathy                  | [57], [216] | 9 | NR in all articles. | Dinkin M et al. [215], reported a 36 Y/O M and third nerve palsy and impression of Miller-Fisher syndrome. |
| 3   | Facial nerve palsy                     | [58], [217] | 4 | NR in all articles. | |
| 4   | Auditory Impairment                   | [62], [57] | 5 | NR in all articles. | |
| 5   | Glossopharyngeal neuralgia             | [57] | 9 | NR | |
| 6   | GBS and GBS variants                  | [60], [63], [101], [191], [215], [218], [219], [220], [221], [222], [223], [224], [225], [226], [227], [228], [229], [230], [231], [232], [233], [234], [235], [236], [237], [238], [239], [240], [241], [242], [243], [244], [245], [246], [247], [248] | 52 | NR in all articles. | Su XW et al [226], reported a patient GBS with dysautonomia. |
| 36  | GBS and other Neuropathies             |          |                |                                  |       |
| 1   | Skeletal muscles injury and Rhabdomyolysis | [39], [58], [60] | 38 | NR in all articles. | Pfefferkorn T, et al. [247] reported a 51 Y/O M acute polyradiculoneuritis. |
| 2   | Myopathy                              | [60], [250], [251] | 28 | NR in all articles. | |
| 3   | Myositis                              | [252] | 1 | 58 Y/O F | 58 Y/O F with muscle biopsy suggestive of Myositis. |
| 4   | Myasthenic crisis                     | [253] | 1 | 56 Y/O F | With history of myasthenia gravis. |
| 5   | Neuroleptic Malignant Syndrome         | [254] | 1 | Middle age man | In patient with past medical history of psychiatric disorders. |

### Table 5
**Complications related to Skeletal Muscles and Neuromuscular Junction (NMJ) Reported During and After SARS-CoV-2 Infection.**

| No. | Neurological Symptom                  | Ref. No. | No. of patients | Mean Age of the patients (Range) | Notes |
|-----|---------------------------------------|----------|----------------|----------------------------------|-------|
| 1   | Symptoms related to Skeletal Muscles and Neuromuscular Junction (NMJ) |          |                |                                  |       |
| 1   | Skeletal muscles injury and Rhabdomyolysis | [39], [58], [60] | 38 | NR in all articles. |       |
| 2   | Myopathy                              | [60], [250], [251] | 28 | NR in all articles. |       |
| 3   | Myositis                              | [252] | 1 | 58 Y/O F |       |
| 4   | Myasthenic crisis                     | [253] | 1 | 56 Y/O F |       |
| 5   | Neuroleptic Malignant Syndrome         | [254] | 1 | Middle age man |       |

### Abbreviation:
M: Male, F: Female, NR: Not reported
J et al. [127], reported a 69-year-old woman with acute necrotizing myelitis.

Optic Neuritis after COVID-19 was reported in only one patient. [60]

3.4.1.4. Impaired consciousness. Decreased level of consciousness and Encephalopathy were reported in 7.5% [39] to 31% [98] of the patients with COVID-19 in 22 articles encompassing 454 patients. (Table 3) Altered consciousness is a general term with several underlying mechanisms. In COVID-19 patients, possible mechanisms include infections, parenchymal damages, electrolyte imbalance, hypoxic, toxic and metabolic encephalopathies and non-convulsive status epilepticus. [58,100,134,135]

Leukoencephalopathy after COVID-19 was reported in 18 patients out of 3 studies. Radmanesh A et al. [145] reported diffuse white matter T2 hyperintensity plus restricted diffusion in 11 critically ill COVID-19 patients. Despite the fact that these findings are nonspecific and that their exact etiology is not certain; they attributed such findings to delayed post-hypoxic leukoencephalopathy. This pattern has been described in patients approximately 10-14 days after a hypoxic insult such as carbon monoxide poisoning, drug overdose, and cardiopulmonary arrests [145] and It is believed to relate to oligodendrogial cell death and subsequently demyelination. Other potential etiologies can be direct cerebral infection, sepsis-associated encephalopathy, post-infectious demyelination, and posterior reversible encephalopathy syndrome (PRES). [145]

Acute Necrotizing Encephalopathy (ANE) which was reported in 8 patients (Table 3) with COVID-19 is a distinct entity defined as rapid onset of neurological symptoms often secondary to a viral infection such as herpes viruses and influenza. Despite the association with viral infection, ANE is usually not considered as an inflammatory encephalitis. The cytokine storm which has been described with SARS-CoV-2 and some other viral infections can cause ANE, particularly in critically ill patients. In the absence of CSF pleocytosis, an intense surge of pro-inflammatory cytokines causes focal damage to the blood-brain barrier and induces edema and subsequent necrosis. [146,147] (Figure 6)

Encephalitis following COVID-19 was reported in 22 patients out of 13 studies. (Table 3) Recently, SARS-CoV-2 was detected in brain tissues and capillary endothelial cells at autopsy and viral infection of CNS was confirmed. [159] Two different potential route of virus entry were suggested; First possible route is through the trigeminal and olfactory nerve endings. Infiltration through the olfactory system could explain the increased FLAIR signal in the medial temporal lobe. Moreover, signal changes which is seen in the brainstem and thalamus may represent a central infiltration through the trigeminal system. [146] The second possible mechanism of viral invasion may be increased permeability of the Blood Brain Barrier (BBB) due to high levels of pro-inflammatory cytokines in the CSF. [146]
Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion (MERS) is suggested to be in relation with various viral infection, electrolyte imbalance disorders, organ failure, and administration of certain medications. [160] In relation with COVID-19, a 75-year-old man with MERS was reported who presented with transient cerebellar ataxia and alteration of consciousness. [160] (Figure 7)

Posterior reversible encephalopathy syndrome (PRES) usually presents with acute impairment in level of consciousness, headache, visual disturbance and seizures. It is usually associated with cortical or subcortical vasogenic edema, involving predominantly the parietal and occipital regions bilaterally. [163] This condition is commonly associated with fluctuation in blood pressure, renal failure, autoimmune conditions, infections and sepsis, preeclampsia or eclampsia and certain type of immunosuppressive-cytotoxic drugs. [163] PRES was reported in ten COVID-19 patients out of 8 studies. (Table 3) Definitive etiology is not fully understood but there are various proposed underlying mechanisms. In COVID-19, endothelial dysfunction related to SARS-CoV-2 in combination with hemodynamic instability and immunological activation with release of cytokines may increase the vascular permeability in the brain tissue. Furthermore, disruption of BBB in these cases may cause vasogenic edema and PRES. [162–163] Kishfy L et al. [165] suggested that COVID-19 patients may be at higher risk of consequences of uncontrolled hypertension such as hypertensive encephalopathy and PRES due to endothelial dysfunction. For this reason, tight blood pressure control was suggested, particularly in ventilated COVID-19 patients.

3.4.1.5. Seizure. Seizure has been reported as a neurological manifestation in patients infected with SARS-CoV-1 [23], MERS-CoV [32] and SARS-CoV-2. In COVID-19, 48 patients out of 20 studies were reported to have seizures. (Table 3). CNS viral infections and subsequent activation of neuro-inflammatory pathways are known to lower the threshold for seizures and potentially facilitate epileptogenesis in certain individuals. [174] As an example, in a COVID-19 patient with prior structural brain damage, focal seizures originating from the lesion site was reported. [175] Moreover, the accumulation of inflammatory markers associated with SARS-CoV-2 infection, may cause a local cortical irritation that precipitates seizures [177]. In addition, viral encephalitis and direct invasion of the virus to the CNS may cause seizure in the affected patients. [177,178] In critically ill COVID-19 patients, metabolic and electrolyte imbalances, ongoing hypoxia and inflammatory/infectious processes may also contribute to seizure or abnormal EEG background. [134]

In a recent study on electroencephalography (EEG) findings of COVID-19 patients by Galanopoulou AS et al. [180], sporadic epileptiform activity, predominantly in the form of frontal sharp waves, were detected in 40.9% of patients with altered mental status. [180]. "Generalized background slowing" particularly in patients with decreased level of consciousness was reported in several investigations.

Fig. 4. CT Angiography of the neck shows macro thrombus within the Common Carotid artery bifurcation extending into the Internal Carotid artery in a previously healthy 33-Year-Old woman. (From Fara MG et al. [95])

M. Sharifian-Dorche, et al. Journal of the Neurological Sciences 417 (2020) 117085

Fig. 5. Fluid-attenuated inversion recovery (FLAIR) mages show diffuse confluent white matter hyperintensity particularly at the left-side (A-D) without significant enhancement on T1-weighted brain MRI (C, F). Involvement of (black arrow), deep gray matter (black arrowhead), and dorsal midbrain (white arrow) is evident. From Abdi S et al. [123]
It was also shown that previous diagnosis of epilepsy can be a potential risk factor for COVID-19-associated seizure.

### 3.4.1.6. Movement disorders

There are few reports about movement disorders in COVID-19. Rábano-Suárez P et al. [182] reported 3 patients with generalized myoclonus with both positive and negative jerks, with predominantly involved the facial, sternocleidomastoid, trapezius, and upper extremities muscles. In those patients, myoclonus occurred spontaneously and were extremely sensitive to multisensory stimuli (auditive and tactile) or voluntary movements. After Immunotherapy, all 3 patients improved, at least partially. [182]

Another study reported [183] a previously healthy 58-year-old man with COVID-19 who developed generalized myoclonus, fluctuating level of consciousness, opsoclonus, right-side dominant hypokinetic-rigid syndrome, and frank hypomimia. The patient also had brief conjugated, multidirectional, and chaotic saccadic ocular movements. DaT-SPECT confirmed bilateral decreased presynaptic dopamine uptake asymmetrically involving bilateral putamen. Parkinsonian symptoms in this patient improved spontaneously without specific treatment. Association between viral infection and Parkinson’s disease was suggested decades ago, namely since the Spanish Flu Pandemic [5]. As mentioned earlier, Fazzini E et al revealed elevated levels of HCoV-OC43 and HCoV-229E antibodies in the CSF of patients with Parkinson’s disease [9]. Given scanty available about such association, no definite conclusion can be drawn.

### 3.4.1.7. CNS Vasculitis

Hanafi R, et al. [185] reported a 65-year-old man with COVID-19 who had extensive diffuse subcortical ischemic lesions in the brain resembling cerebral vasculitis. (Figure 8) He also developed a characteristic lower extremity skin rash. SARS-CoV-2 infects the host through its CoV spike glycoprotein, which binds to the ACE2 receptor. ACE2 receptor has higher expression in neurons and cerebral vessel endothelial cells which can cause high level of CNS invasion. [185,186] Histologic evidence of COVID-19-induced vasculitis has been reported in several other organs including lung, kidney, liver and skin. [186] Similarly, virus-related endothelial injury and endotheliitis might cause CNS vasculitis.

### 3.4.1.8. Cranial Nerves abnormalities

Anosmia and Ageusia, the prevalence of anosmia and ageusia ranges widely in different studies.
from 5% in a study from China [39] to about 88% in an Italian study [56]. Smell impairment was also reported in SARS-CoV-1 and influenza infections. [27] Anosmia was reported in 3730 patients out of 28 studies in the case of SARS-CoV-2. (Table 3) In COVID-19, anosmia is typically not accompanied by nasal swelling or rhinitis and based the findings of several studies it is an important common early clinical presentation even in the absence of other respiratory symptoms. [209] several studies reported that anosmia was more common among females, younger and non-hospitalized patients. [211,214] In most patients, anosmia went away on its own within 3 weeks. [211] MRI abnormalities of the olfactory bulb of COVID-19 patients have been reported in several studies. [207] Politi SL et al. [209], reported a 25-year-old female with anosmia and subtle hyper-intensity signal in the olfactory bulbs and also cortical hyper-intensity in the right gyrus rectus. In follow-up MRI after 28 days, the olfactory bulbs were thinner and slightly less hyper-intense and the signal alteration in the cortex had completely disappeared. (Figure 9) The olfactory system is also considered as a potential route of virus entry. Various studies suggested that CoV may have CNS direct invasion via olfactory bulb. [146,159] Visual Impairments after COVID-19 was reported in 12 patients out of 3 studies. Selvaraj V et al. [204] reported a middle aged woman with COVID-19 who presented with sudden onset painless right eye monocular visual blurrines. Brain and orbit MRIs were unremarkable and eye examinations were normal, posterior ischemic optic neuropathy was considered as the cause. Thromboembolic events, systemic inflammation associated with COVID-19 and invasion of CoV to the CNS through the hematogenous route or direct invasion through the cribriform plate or conjunctiva were considered the potential underlying mechanisms. [204]

3.4.2. Symptoms Associated with Peripheral Nervous System (PNS)

3.4.2.1. Cranial Nerve abnormalities. Impaired Eye movement associated with COVID-19 was described in 12 patients out of 4 studies. (Table 3) Pascual-Goni E et al. [194], reported a 60-year-old woman with right abducens nerve palsy. In brain MRI examination, FLAIR hyper-intensity of the pontine tegmentum and right sixth cranial nerve nucleus was noted. Trigeminal neuropathy was reported in 9 patients out of 2 studies. (Table 3) de Freitas Ferreira ACA et al. [216] reported a 39-year-old man with trigeminal neuropathy associated with SARS-Cov-2 and herpes zoster co-infection.

3.4.2.2. Guillain-Barré Syndrome (GBS). GBS can occur post gastrointestinal or respiratory illness. The suggested mechanism is molecular mimicry in which the pathogen likely share epitopes similar to the components of the peripheral nerves. The antibodies produced by the host immune system to fight the virus, cross-react and bind to the peripheral nerves causing neuronal dysfunction. [249] AIDP and AMAN variants have been reported after SARS-CoV-1 and MERS-CoV infections. [25,34,46] Concerning COVID-19, 52 patients out of 36 studies were described to have different variants of GBS. (Table 3) Miller Fisher Syndrome was also reported in several cases. [101,228,237,239,246]
3.4.3. Symptoms associated with Skeletal Muscle and Neuromuscular Junction (NMJ)

Skeletal muscle injury and myopathy have been reported in COVID-19 patients. (Table 5) In the severe COVID-19 patients, critical illness myopathy has been reported. Major proposed risk factors for this type of myopathy are severe respiratory distress, systemic inflammatory response and sepsis. [250,251] Moreover direct invasion of the muscle by the virus is the other potential mechanism for myopathy. Similar to SARS-CoV-1, SARS-CoV-2 have the ability to penetrate the cells that express ACE2 receptors. As ACE2 is expressed in the muscle cells, the possibility of invasion of the muscles by the virus entering the cells via the ACE2 receptors should also be considered. In addition, hyper-inflammation and cytokine storms in the advanced phase of COVID-19 could cause immune-mediated muscle damage. [250] Considering the growing number of patients with COVID-19, myopathy should be considered as a major cause of long-term physical disability [251].

4. Similarities between neurological manifestations of CoV infections

There are several similarities between neurological manifestations of different CoV infections. encephalitis was reported in HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2 infections. [15,16,24,33,60,98,100,150,151,152,153,154,155,156,157,158] ADEM was reported after HCoV-OC43 and SARS-CoV-2 infection. [17,120,121,122,123] Headache, ischemic stroke, encephalitis and encephalopathy, seizure and neuropathy were reported in all the pandemics associated with CoV (SARS-CoV-1, MERS-CoV and SARS-CoV-2). ICH was reported in MERS-CoV and COVID-19 and myopathy and anosmia were reported in SARS-CoV-1 and COVID-19. (Figure 10)

Limitations

In this review, we tried to gather and summarize the results of all the studies reporting neurological disorders observed in patients with CoV infections. However, in some of the reported patients, the neurological manifestations might not be associated with the CoV infections and just coincidentally occurred due to the patient’s underlying comorbidities. Moreover, in patients with severe CoV infections, the associated sepsis and organs failure may lead to different neurological presentations which can be seen in any of critical conditions. In addition, in several studies, particularly in the case of COVID-19, sufficient investigations have not been performed and hard to believe that the neurological manifestation was related to CoV infection. Finally, yet importantly, the neurological symptoms in some of these patients might be medications side effects given CoV infected patients have been treated with different classes of medications, which have side effects, not necessarily reported in the studies.

5. Conclusion

There are similarities between the neurological complications
associated with SARS-CoV-1, MERS-CoV and COVID-19. However, the scope of the pandemics and number of patients involved in each are different. Thus far, SARS-CoV-2 has infected millions of people worldwide. Reports on the neurological complications after and during COVID-19 are growing on a daily basis. Better understanding of the potential associated neurological complications will help health care providers to be more attentive to these complications and a more timely diagnosis and management. Sources of funding None. Declaration of Competing Interest Authors have no relevant financial disclosure to report.

References
[1] E.A. Troyer, J.N. Kohn, S. Hong, Are we facing a crashing wave of neuropathological sequels of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms, Brain Behav Immun. 87 (2020) 34–39 S0899- 1591(20)30498-X. X. 1591. [2] P. Martin, E. Martin-Granet, 2,500-year evolution of the term epidemic, Emerg Infect Dis 12 (6) (2006) 976–980. [3] B.A. Cunha, Influenza: historical aspects of epidemics and pandemics, Infect Dis Clin North Am. 18 (1) (2004 Mar) 141–155. [4] E.B. Turner, Discussion on Influenza, Proc R Med. 12 (1919) 76–78. [5] H. Jang, D.A. Bolte, R.G. Webster, R.J. Swayne, Viral parkinsonism, Biochim Biophys Acta. 1792 (7) (2009 Jul) 714–721. [6] J.S. Kahn, K. Mcintosh, “History and recent advances in coronavirus discovery”: The Pediatric Infectious Disease Journal, Pediatr Infect Dis J. 24 (11 Suppl) (2005) S223-7, discussion S226. [7] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med. 382 (8) (2020) 727–733. https://doi.org/10.1056/NEJMa2001017. [8] B. Hutton, G. Salanti, D.M. Caldwell, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann. Intern. Med. 162 (2015) 777–784. [9] E. Fazzini, J. Fleming, S. Fahn, Cerebrospinal fluid antibodies to coronavirus in multiple sclerosis patients, New Microbiol. 20 (2) (1997 Apr) 105–114. [10] J.S. Burks, B.L. DeVald, L.K. Tsai, Y.H. Chiou, M.T. Tseng, S.C. Chang, et al., Myopathic and Neuropathic Syndromes Associated With Coronavirus Disease 2019 (COVID-19) in Wuhan, China, JAMA Neurol. 77 (6) (2020 Apr 10) 1–9 s011127. [11] N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, China: a descriptive study, Lancet 395 (2020) 507–513. [12] C. Huang, Y. Wang, X. Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet. 395 (2020) 477–481. [13] X. Yang, Y. Yu, J. Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective observational study, Lancet Respir. Med. 8 (5) (2020 May) 475–481. [14] D. Wang, B. Hu, C. Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA. 323 (11) (2020 Mar 17) 1061–1068. [15] Y. Deng, W. Liu, K. Liu, Y. Fang, J. Yang, L. Zhou, et al., Clinical Characteristics of Fatal and Recovered Cases of Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Retrospective Study, Chin Med J (Engl) 133 (11) (2020 Jun 15) 1261–1267. [16] W.J. Guan, Z.Y. Ni, Y. Hu, W. Liang, C. Ou, J. He, et al., clinical characteristics of 2019 novel coronavirus infection in China, N Engl J Med 382 (8) (2020 Apr 30) 1708–1720 2002.0662.20020974. [17] D. Chang, M. Lin, L. Wei, Z. Wang, Y. Liang, T. Huang, et al., Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China, JAMA. 323 (11) (2020 Mar 17) 1061–1068. [18] G. Zhang, S. Nie, Z. Zhang, Z. Zhang, Longitudinal Change of SARS-CoV-2 Antibodies in Patients with COVID-19, Infect Dis. 222 (2) (2020 Jun 29) 183–188. [19] L. Sun, L. Shen, J. Fan, F. Gu, M. Hu, Y. An, et al., Clinical Features of Patients With Coronavirus Disease 2019 (COVID-19) from a Designated Hospital in Beijing, Clin Med (Lond). 20 (2) (2020 May 1–12) 2020. https://doi.org/10.7791/cm-2020-00502. [20] M.J. Cummings, M.R. Baldwin, D. Abrams, S.D. Jacobson, B.J. Meyer, E.M. Balough, et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet 395 (10239) (2020 Jun 6) 1763–1770 S0140-6736(20)30819-2. [21] R. Huang, L. Zhu, L. Xue, L. Liu, Y. Yan, J. Wang, et al., Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multicenter study, PLoS Negl Trop Dis. 14 (5) (2020 May 8) e0008280. [22] H. Kato, H. Shirimizu, Y. Shihue, T. Hosoda, K. Iwabuchi, K. Nagamine, et al., Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship, J Infect Chemother. 26 (6) (2020 Aug) 865–869.
patients with SARS-CoV-2 infection: case series, J Neurol. 267 (8) (2020 Aug) 2182–2192, https://doi.org/10.1007/s00415-020-09885-2.

[80] T. Osley, J. Mocco, S. Majidi, C. Kellner, H. Shoirah, P. Singh, et al., Large-Vessel Stroke as a Presenting Feature of COVID-19 in the Young, N Engl J Med. 382 (20) 1595–1602, https://doi.org/10.1056/NEJMc2010683.

[81] M.F. Goldberg, M.F. Goldberg, R. Cerezee, A.H. Tayal, Cerebrovascular Disease in COVID-19, AJNR Am J Neuroradiol. 41 (7) (2020 Jul) 1170–1172, https://doi.org/10.3174/ajnr.A6588.

[82] P. Modiayed, T.E. Rickard, L.P. Mejia, M. Nour, D.S. Liebeskind, Tragic of Acute Ischemic Stroke in Confirmed COVID-19: Large Vessel Occlusion Associated with Coronavirus Infection, Front Neurol. 11 (2020 Apr) 255.

[83] F. Klok, M. Kruip, N. van der Meer, M. Arbous, D. Gommers, K. Kant, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thorax. 75 (2020) 145–147, https://doi.org/10.1136/thoraxjnl-2020-211082.

[84] C. Lodigiani, G. Lapichino, L. Carenzo, M. Cecconi, P. Ferrazzi, T. Sebastian, Viral and arteriolar thromboembolic complications in 19 COVID-19 patients admitted to an academic hospital in Milan, Italy, Thorax. 191 (2020) 9–14, https://doi.org/10.1136/thoraxjnl-2020-212594.

[85] F. Sierra-Hidalgo, N. Muñoz-Rivas, P. Torres Rubio, K. Chao, M. Villanova Martínez, P. Arranz García, et al., Large artery ischemic stroke in severe COVID-19, J. Neurol. (2020 Jun) 1–3, https://doi.org/10.1007/s00415-020-09967-1.

[86] P. Immovilli, M. Terracciano, D. Zaino, E. Marchesi, N. Morelli, E. Terlizzi, et al., Stroke in COVID-19 patients: a case series from Italy, Int J Stroke. 15 (6) (2020) 701–702, https://doi.org/10.1177/1747493020938294.

[87] F. Cavalleri, A. Marti, A. Fasano, A.D. Salda, A. Ghiraduzzi, C. Moratti, et al., Prothrombotic state induced by COVID-19 infection as trigger for stroke in young patients: A dangerous association, eNeurological Sci. 20 (2020 Jun) 100247.

[88] W. Klok, M. Kruip, J. Li, J. Groot, T. van Dijk, A. Bonten, et al., Incidence of thrombotic events in people with COVID-19 infection in three regions in China, Neurology. (2020 Jun) 17, https://doi.org/10.1212/WNL.

[89] O.H. Williams, S. Mohiden, A. Sen, O. Martinovic, J. Hart, P.A. Brex, et al., Multiple internal border zone infarctions in a patient with COVID-19 and CADASIL, J Neurol. 416 (2020 Jun) 11 69680.

[90] A. Sharifi-Razavi, N. Karimi, A. Zarvari, H. Cheraghamaki, S.M. Baghbanian, Ischemic Stroke Associated With Novel Coronavirus 2019: A Report of Three Cases, Int J Neurol. (2020) 1–4, https://doi.org/10.1016/j.jiuron.2020.05.017.

[91] M. Guillon, J. Villacézar-Villoria, S. Bellido, C. Perez-Jorge; Peramensch, V.M. Suarez-Vega, M. Aragones-Garcia, et al., Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient, Thorax. 193 (2020 Sep) 107–109, https://doi.org/10.1136/thoraxjnl-2020-216814.

[92] A.M. Franceschi, R.A. Arora, R. Wilson, L. Giliberto, R.B. Libman, M. Castillo, Neurovascular Complications in COVID-19 Infection: Case Series, AJNR Am J Neuroradiol. (2020 Jun), https://doi.org/10.3174/ajnr.A6462.

[93] M. Khan, R.H. Ibrahim, S.A. Siddiqi, Y. Kerolos, M.M. Al-Kaylani, S.A. AlRukn, et al., Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Observational Study, Stroke. 51 (2020 Jul) 2117–2122, https://doi.org/10.1161/STROKEAHA.120.030159.

[94] E. Cantador, A. Núñez, P. Esposejo, L. Fabia, V. Vela, et al., Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients, J Thromb Thrombolysis. (2020 Jun) 1–5, https://doi.org/10.1007/s11239-020-09889-8.

[95] A. Sharifi-Razavi, N. Karimi, A. Zarvari, H. Cheraghamaki, S.M. Baghbanian, Ischemic Stroke Associated With Novel Coronavirus 2019: A Report of Three Cases, Int J Neurol. (2020) 1–4, https://doi.org/10.1016/j.jiuron.2020.05.017.

[96] M. Guillon, J. Villacézar-Villoria, S. Bellido, C. Perez-Jorge; Peramensch, V.M. Suarez-Vega, M. Aragones-Garcia, et al., Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient, Thorax. 193 (2020 Sep) 107–109, https://doi.org/10.1136/thoraxjnl-2020-216814.

[97] E. Cantador, A. Núñez, P. Esposejo, L. Fabia, V. Vela, et al., Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients, J Thromb Thrombolysis. (2020 Jun) 1–5, https://doi.org/10.1007/s11239-020-09889-8.

[98] M. Khan, R.H. Ibrahim, S.A. Siddiqi, Y. Kerolos, M.M. Al-Kaylani, S.A. AlRukn, et al., Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Observational Study, Stroke. 51 (2020 Jul) 2117–2122, https://doi.org/10.1161/STROKEAHA.120.030159.

[99] A.M. Franceschi, R.A. Arora, R. Wilson, L. Giliberto, R.B. Libman, M. Castillo, Neurovascular Complications in COVID-19 Infection: Case Series, AJNR Am J Neuroradiol. (2020 Jun), https://doi.org/10.3174/ajnr.A6462.

[100] M. Khan, R.H. Ibrahim, S.A. Siddiqi, Y. Kerolos, M.M. Al-Kaylani, S.A. AlRukn, et al., Neurological Disease of Hospitalized COVID-19 Patients: An Italian Multicenter Observational Study, Stroke. 51 (2020 Jul) 2117–2122, https://doi.org/10.1161/STROKEAHA.120.030159.

[101] F. Cavalleri, A. Marti, A. Fasano, A.D. Salda, A. Ghiraduzzi, C. Moratti, et al., Prothrombotic state induced by COVID-19 infection as trigger for stroke in young patients: A dangerous association, eNeurological Sci. 20 (2020 Jun) 100247.

[102] M. Malentacchi, D. Gned, V. Angelino, S. Demichelis, A. Perboni, A. Veltri, et al., Clinical and virological characteristics of 74 cases of coronavirus-infected disease in Wuhan, China: Retrospective case series, BMJ. 368 (2020) m606.

[103] R. Beyrouti, M.E. Adams, L. Benjamin, H. Cohen, S.F. Farmer, Y.Y. Goh, et al., Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection, Brain Behav Immun. 88 (2020 Aug) 11–16, https://doi.org/10.1016/j.bbi.2020.05.037.

[104] A.N. Kochi, A.P. Tagliari, G.B. Forleo, G.M. Fassini, C. Tondo, Cardiac and arterial complications in COVID-19 patients: a dangerous association, eNeurological Sci. 20 (2020 Jun) 100247.
A. Agarwal, V.Y. Vishnu, D. Vibha, R. Bhatia, A. Gupta, A. Das, M.V.P. Srivastava, S. Muhammad, A. Petridis, J.F. Cornelius, D. Hänggi, Letter to editor: Severe brain
Cavalcanti DD, Raz E, Shapiro M, Dehkharghani S, Yaghi S, Lillemoe K, et al., A. Zoghi, M. Ramezani, M. Roozbeh, I.A. Darazam, M.A. Sahraian, A case of COVID-19 pneumonia in the young female patient with COVID-19 infection in Downtown Los Angeles, early April 2020, Brain Behav Immun. 88 (2020) S0889-1591(20)30797-7.

I. Li, X. Long, C. Zhu, S. Hu, Z. Lin, J. Li, N. Xiong, A case of COVID-19 pneumonia with cerebral hemorrhage, Thromb Res. 193 (2020 May 30) 22–24.

A. Guaraglia, P. Veschina, D. Viliba, R. Bhatia, A. Gupta, A. Das, M.V.P. Srivastava, Intracerebral Hemorrhage and SARS-CoV-2: Association or Causation, Ann Indian Acad. Neurol. 23 (3) (2020 May-Jun) 261–264.

M. Benguer, O. Yusef, M. Siddiqui, L. Satria, Intracerebral haemorrhage and COVID-19: Clinical characteristics from a case series, Brain Behav Immun. 88 (2020 Aug) 940–944, https://doi.org/10.1016/j.bbi.2020.06.005, S0889-1591(20)30107-9.

J. Li, J. Long, C. Zhu, S. Hu, Z. Lin, J. Li, N. Xiong, A case of COVID-19 pneumonia with cerebral hemorrhage, Thromb Res. 193 (2020 May 30) 22–24.

N. Poyiadji, G. Shahin, D. Noujaim, M. Stone, B. Patel, B. Griffith, COVID-19-associated acute necrotizing leukoencephalopathy, Neurol Neuroimmunol Neuroinflamm. 7 (4) (2020 May 15) e761.

A. Sharifi-Razavi, N. Karimi, N. Rouhani, COVID 19, and intracerebral hemorrhage: A case report, Acta Neurochir (Wien). 162 (7) (2020 Jul) 1495–1499, https://doi.org/10.1007/s00701-020-04402-w.

S. Ahmad, B. Leurent, E.L. Sampson, Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis, Age Ageing. 43 (3) (2014) 326–333.

M. Hayashi, Y. Sahashi, Y. Baba, H. Okura, T. Shimohata, COVID-19-associated delay posthypoxic encephalopathy, Cerebrovasc Dis. 94 (2020 May) 55–58.

A. Radmanesh, A. Derman, Y.W. Lui, E. Raz, J.P. Loh, M. Hagiwara, et al., COVID-19-associated Diffuse Leukoencephalopathy and Microhemorrhages, Radiology. (2020) 21 (2020 May 21) 202040, https://doi.org/10.1148/radiol.20202040.

J. Virhammar, E. Kumljen, D. Fallmar, R. Frithiof, S. Jackmann, M.K. Sköld, et al., Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid, Neurological Fluid, (2020 Jun), https://doi.org/10.1212/WNL.0000000000009323.

R. Rieckard, K.B. Kashani, N.A. Boire, E. Constantopoulos, Y. Guo, C.F. Lucchinetti, Neuropathology of COVID-19: A spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology, Acta Neuropathol. 140 (4) (2020) 1–6, https://doi.org/10.1007/s00401-020-02166-z.

A. Radmanesh, A. Derman, Y.W. Lui, E. Raz, J.P. Loh, M. Hagiwara, et al., COVID-19-associated acute necrotizing leukoencephalopathy, Radiology. (2020 May 14) 20201753, , https://doi.org/10.1148/radiol.2020201753.

A. Radmanesh, A. Derman, Y.W. Lui, E. Raz, J.P. Loh, M. Hagiwara, et al., COVID-19-associated Diffuse Leukoencephalopathy and Microhemorrhages, Radiology. (2020 May 21) 202040, , https://doi.org/10.1148/radiol.20202040.

A. Zachariadis, A. Tulbu, D. Strambo, A. Dumoulin, G. Di Virgilio, Transverse myelitis related to COVID-19 infection, J Neurol. (2020 Jun 4) 1–3, https://doi.org/10.1007/s00701-020-04402-w.

A. Filatov, P. Sharma, F. Hindi, P.S. Espinosa, Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, Caselets. 12 (3) (2020 Mar 21) e7352.

L. Lu, W. Xiong, D. Liu, J. Liu, D. Yang, N. Li, et al., New onset acute symptomatic seizures and risk factors in coronavirus disease 2019: A retrospective multicenter study, Epilepsia. 61 (6) (2020 Jun) e49–e53, https://doi.org/10.1111/epi.16524.

A. Sharifi-Razavi, N. Karimi, N. Rouhani, COVID 19, and intracerebral hemorrhage: A case report, Acta Neurochir (Wien). 162 (7) (2020 Jul) 1495–1499, https://doi.org/10.1007/s00701-020-04402-w.

A. Filatov, P. Sharma, F. Hindi, P.S. Espinosa, Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, Caselets. 12 (3) (2020 Mar 21) e7352.

A. Filatov, P. Sharma, F. Hindi, P.S. Espinosa, Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, Caselets. 12 (3) (2020 Mar 21) e7352.
L. Princicuta Caridi, P. Tabare Damavandi, F. Cicarini, P. Banfi, A. Clemenzi, M. Marelli, et al., Reversible Encephalopathy Syndrome (RES) in a COVID-19 Patient, J Neurol. (2020 Jun 24) 1–4.

S. Gómez-Enjuto, V. Hernando-Requejo, J. Lapeña-Motilva, G. Ogando-Durán, D. Piñeyro, J. Martínez-Poles, et al., Cerebrovascular changes in acute hyperoxic respiratory failure treated with fullplateau strategy in a patient with COVID-19, J Neurol. (2020 Jun 8) 115–119.

K. Nishida, S. Yamaoka, K. Kawanami, H. Saka, A. Takano, M. Hattori, et al., Patient at risk for severe COVID-19: A case report, BJNeuro. (2020 Jun 28) 1–5.

S. Maruyama, N. Kuchihara, K. Fujiwara, K. Washizuka, T. Sato, Y. Suzuki, et al., Aldosteronoma in a patient with COVID-19: a case report, Intern Med. (2020 Jun 28) 1–6.

S. Gómez-Enjuto, J.L. Chico-García, M. Porta-Etessam, T. Montalvo, A. Valls-Carbó, V. Gajate, et al., A novel syndrome? Rhinology. 58 (3) (2020 Jun 1) 299–301, https://doi.org/10.1179/0300699019Y.0000000183.

K. Tanaka, T. Yamamoto, N. Morita, T. Nakamura, Y. Nakanishi, T. Toyama, et al., A case of acute respiratory failure due to severe COVID-19 infection, Intern Med. (2020 Jun 28) 1–4.

S. Gómez-Enjuto, J.L. Chico-García, M. Porta-Etessam, T. Montalvo, A. Valls-Carbó, V. Gajate, et al., A novel syndrome? Rhinology. 58 (3) (2020 Jun 1) 299–301, https://doi.org/10.1179/0300699019Y.0000000183.

S. Maruyama, N. Kuchihara, K. Fujiwara, K. Washizuka, T. Sato, Y. Suzuki, et al., Aldosteronoma in a patient with COVID-19: a case report, Intern Med. (2020 Jun 28) 1–5.

S. Gómez-Enjuto, J.L. Chico-García, M. Porta-Etessam, T. Montalvo, A. Valls-Carbó, V. Gajate, et al., A novel syndrome? Rhinology. 58 (3) (2020 Jun 1) 299–301, https://doi.org/10.1179/0300699019Y.0000000183.
Guillain-Barré syndrome associated with COVID-19 infection, Eur J Neurol. (2020 Jun 13), https://doi.org/10.1111/ene.

R. Hebék, R. Beer, W. Löscher, S. Boesch, M. Reindi, R. Hornung, et al., Guillain-Barré Syndrome in a Patient With Antibodies Against SARS-COV-2, Eur J Neurol. (2020 Jun 12), https://doi.org/10.1111/ene.14198.

P. Manganocti, P. Pesavento, A. Buoste Stella, L. Bonzi, E. Campagnolo, G. Bellavita, et al., Miller Fisher Syndrome Diagnosis and Treatment in a Patient With SARS-CoV-2, J Neurol. (2020 Jun 11) 1–2.

A. Anisi, L. Benedetti, S. Di Maio, E. Schirini, M. Del Sette, Correction to: New clinical manifestation of COVID-19 related Guillain-Barré syndrome highly responsive to intravenous immunoglobulins: two Italian cases, Neurol Sci. (2020 Jun 6) 1.

J.A. Reyes-Bueno, L. García-Trujillo, P. Urbaneja, N.L. Giano-Petersen, M.J. Postigo-Pozo, C. Martínez-Tomás, et al., Miller-Fisher syndrome after SARS-CoV-2 infection, Eur J Neurol. (2020 Jun 5), https://doi.org/10.1111/ene.14383.

E. Ongou-Akarou, R. Ospar, H. Mirzayev, N.A. Acet-Ozturk, B. Halyemen, D. Ediger, et al., Guillain-Barré Syndrome in a Patient With Minimal Symptoms of COVID-19 Infection, Muscle Nerve. (2020 Jun 4), https://doi.org/10.1002/mus.26992.

A.M. Lascano, J.B. Epiney, M. Goen, J. Serratrice, R. Bernard-Valent, P.H. Lalive, et al., SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with favorable outcome, Eur J Neurol. (2020 Jun 1), https://doi.org/10.1111/ene.14368.

S. Rana, A.A. Lima, R. Chandra, J. Valeriano, T. Desai, W. Freiberg, et al., Novel Coronavirus (COVID-19)-Associated Guillain-Barré Syndrome: Case Report, J Clin Neuromuscul Dis. 21 (4) (2020 Jun) 240–242.

G.L. Gigli, F. Bax, A. Marinii, G. Pellitteri, A. Scialisi, A. Scirincelli, et al., Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? J Neurol. (2020 May 19) 1–3.

M. Pedroni, V. Mastrangelo, G.M. Ascoli, L. Pavulucci, S. Abu-Bumelsh, M.G. Fiscaglia, et al., Guillain-Barré syndrome following COVID-19: new infection, old complication? J Neurol. 267 (7) (2020 Jul) 1877–1879.

S. Paybarth, R. Gorgi, S. Mayavand, Guillain-Barré Syndrome as a Neurological manifestation of COVID-19 infection: A Case Report and Review of the Literature, Neurologist. 25 (4) (2020 Jul) 101–103.

J.E. Santos, S.B. Strauss, E. Lin, COVID-19-Associated Miller Fisher Syndrome: MRI Findings, AJNR Am J Neuroradiol. 41 (7) (2020 Jul) 1184–1186.

T. Pleifferhorn, R. Dahüt, T. von Wernitz-Keibel, J. Aufenanger, M. Nowak-Machen, H. Janssen, Acute polyradiculoneuritis with locked-in syndrome in a patient with Covid-19, J Neurol. (2020 May 12) 1–2, https://doi.org/10.1007/s00415-020-09897-y.

I. Abdellouar, M. Abdalla, S. Babiker, COVID 19 infection presenting as motor peripheral neuropathy, J Formos Med Assoc. 119 (6) (2020 Jun) 1119–1120, https://doi.org/10.1016/j.jfma.2020.04.024.

A.S. Zuber, L.S. McAlpine, T. Gardin, S. Farhadian, D.E. Kuruvilla, S. Spudich, Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review, JAMA Neurol. (2020 May 29), https://doi.org/10.1001/jamaneurol.2020.2065.

F. Madia, B. Merico, G. Primiano, S.L. Cutuli, G. De Pascuale, S. Servidei, Acute myopatic quadriparesis in COVID-19 patients in the intensive care unit, Neurology. (2020 Jun 29) 10.

H. Tankin, A. Tankin, T. Harbo, L.K. Markvardsen, H. Andersen, T.H. Pedersen, Critical illness myopathy as a consequence of Covid-19 infection, Clin Neurophysiol. 131 (8) (2020 Jun 12) 1931–1932.

H. Zhang, Z. Charachmi, R.J. Seidman, Y. Anziska, V. Velayudhan, J. Perk, COVID-19-associated myositis with severe proximal and bulbar weakness, Muscle Nerve. (2020 Jun 14), https://doi.org/10.1002/mus.27003.

F. Delly, M.J. Syed, P. Lepicard, D. Lassalle, Myasthenic crisis in COVID-19, J Neurol. Sci. 414 (2020 May 6) 116888.

R. Kajani, A. Apramian, A. Vega, N. Ushuyakar, P. Xu, A. Liu, Neuroleptic malignant syndrome in a COVID-19 patient, Brain Behav Immun. 88 (2020) 28–29, https://doi.org/10.1016/j.bbi.2020.05.042.